Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

Neurological Manifestations of Arsenic Intoxication Medication

  • Author: Frances M Dyro, MD; Chief Editor: Tarakad S Ramachandran, MBBS, MBA, MPH, FAAN, FACP, FAHA, FRCP, FRCPC, FRS, LRCP, MRCP, MRCS  more...
 
Updated: Nov 02, 2015
 

Medication Summary

The treatment of acute toxicity from arsenic consists primarily of maintaining hydration and electrolyte balance. The use of chelating agents hastens the removal of arsenic from the system. Management of arsine toxicity generally addresses the acute hepatorenal complications. The use of chelating agents in these cases is debatable.

Next

Chelation agents

Class Summary

These are substances that bind heavy metals in the plasma and render them nontoxic; they also aid in their excretion.

Dimercaprol (BAL in Oil)

 

British antilewisite is agent of choice in United States. Used as chelator for other heavy metals and stocked as essential item in emergency departments and poison control centers.

Succimer (Chemet)

 

Licensed by FDA as chelating agent for lead poisoning in children; used successfully to treat arsenic intoxication as well; available as 100-mg capsule.

Penicillamine (Cuprimine, Depen)

 

Metal chelator used to treat arsenic poisoning; forms soluble complexes with metals excreted in urine.

Previous
 
 
Contributor Information and Disclosures
Author

Frances M Dyro, MD Associate Professor of Neurology, New York Medical College; Physician, Neuromuscular Section, Department of Neurology, Westchester Medical Center

Frances M Dyro, MD is a member of the following medical societies: American Academy of Neurology, American Association of Neuromuscular and Electrodiagnostic Medicine

Disclosure: Nothing to disclose.

Specialty Editor Board

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Glenn Lopate, MD Associate Professor, Department of Neurology, Division of Neuromuscular Diseases, Washington University School of Medicine; Consulting Staff, Department of Neurology, Barnes-Jewish Hospital

Glenn Lopate, MD is a member of the following medical societies: American Academy of Neurology, American Association of Neuromuscular and Electrodiagnostic Medicine, Phi Beta Kappa

Disclosure: Nothing to disclose.

Chief Editor

Tarakad S Ramachandran, MBBS, MBA, MPH, FAAN, FACP, FAHA, FRCP, FRCPC, FRS, LRCP, MRCP, MRCS Professor Emeritus of Neurology and Psychiatry, Clinical Professor of Medicine, Clinical Professor of Family Medicine, Clinical Professor of Neurosurgery, State University of New York Upstate Medical University; Neuroscience Director, Department of Neurology, Crouse Irving Memorial Hospital

Tarakad S Ramachandran, MBBS, MBA, MPH, FAAN, FACP, FAHA, FRCP, FRCPC, FRS, LRCP, MRCP, MRCS is a member of the following medical societies: American College of International Physicians, American Heart Association, American Stroke Association, American Academy of Neurology, American Academy of Pain Medicine, American College of Forensic Examiners Institute, National Association of Managed Care Physicians, American College of Physicians, Royal College of Physicians, Royal College of Physicians and Surgeons of Canada, Royal College of Surgeons of England, Royal Society of Medicine

Disclosure: Nothing to disclose.

Additional Contributors

Jonathan S Rutchik, MD, MPH Associate Clinical Professor, Division of Occupational Medicine, Department of Medicine, University of California, San Francisco, School of Medicine; Neurology, Environmental and Occupational Medicine Associates (www.neoma.com)

Jonathan S Rutchik, MD, MPH is a member of the following medical societies: American Academy of Neurology, American Association of Neuromuscular and Electrodiagnostic Medicine, International Parkinson and Movement Disorder Society, Society of Toxicology, Western Occupational and Environmental Medical Association, American College of Occupational and Environmental Medicine

Disclosure: Nothing to disclose.

References
  1. Ford M. Arsenic. In: Goldfrank LR, Flomenbaum NE, et al, eds. Toxicologic Emergencies. 1994:1011-1029.

  2. Axelson O, Dahlgren E, Jansson CD, Rehnlund SO. Arsenic exposure and mortality: a case-referent study from a Swedish copper smelter. Br J Ind Med. 1978 Feb. 35(1):8-15. [Medline].

  3. Bae M, Watanabe C, Inaoka T, et al. Arsenic in cooked rice in Bangladesh. Lancet. 2002 Dec 7. 360(9348):1839-40. [Medline].

  4. Franzblau A, Lilis R. Acute arsenic intoxication from environmental arsenic exposure. Arch Environ Health. 1989 Nov-Dec. 44(6):385-90. [Medline].

  5. Heinrich-Ramm R, Mindt-Prufert S, Szadkowski D. Arsenic species excretion in a group of persons in northern Germany-- contribution to the evaluation of reference values. Int J Hyg Environ Health. 2001 Jul. 203(5-6):475-7. [Medline].

  6. Ball P. Arsenic-free water still a pipedream. Nature. 2005 Jul 21. 436(7049):313. [Medline].

  7. Fowler BA, Weissberg JB. Arsine poisoning. N Engl J Med. 1974 Nov 28. 291(22):1171-4. [Medline].

  8. Heyman A, Pfeiffer JB, Willett RW, Taylor HM. Peripheral neuropathy caused by arsenical intoxication; a study of 41 cases with observations on the effects of BAL (2, 3, dimercapto-propanol). N Engl J Med. 1956 Mar 1. 254(9):401-9. [Medline].

  9. Chen CJ, Wu MM, Lee SS, et al. Atherogenicity and carcinogenicity of high-arsenic artesian well water. Multiple risk factors and related malignant neoplasms of blackfoot disease. Arteriosclerosis. 1988 Sep-Oct. 8(5):452-60. [Medline].

  10. Watanabe C, Kawata A, Sudo N, et al. Water intake in an Asian population living in arsenic-contaminated area. Toxicol Appl Pharmacol. 2004 Aug 1. 198(3):272-82. [Medline].

  11. Donofrio PD, Wilbourn AJ, Albers JW, et al. Acute arsenic intoxication presenting as Guillain-Barre-like syndrome. Muscle Nerve. 1987 Feb. 10(2):114-20. [Medline].

  12. Bates MN, Smith AH, Hopenhayn-Rich C. Arsenic ingestion and internal cancers: a review. Am J Epidemiol. 1992 Mar 1. 135(5):462-76. [Medline].

  13. Enterline PE, Henderson VL, Marsh GM. Exposure to arsenic and respiratory cancer. A reanalysis. Am J Epidemiol. 1987 Jun. 125(6):929-38. [Medline].

  14. Karagas MR, Le CX, Morris S, et al. Markers of low level arsenic exposure for evaluating human cancer risks in a US population. Int J Occup Med Environ Health. 2001. 14(2):171-5. [Medline].

  15. Argos M, Kalra T, Rathouz PJ, Chen Y, Pierce B, Parvez F, et al. Arsenic exposure from drinking water, and all-cause and chronic-disease mortalities in Bangladesh (HEALS): a prospective cohort study. Lancet. 2010 Jul 24. 376(9737):252-8. [Medline].

  16. Grandjean P, Landrigan PJ. Developmental neurotoxicity of industrial chemicals. Lancet. 2006 Dec 16. 368(9553):2167-78. [Medline].

  17. Kyle RA, Pease GL. Hematologic aspects of arsenic intoxication. N Engl J Med. 1965 Jul 1. 273:18-23. [Medline].

  18. Massey EW. Arsenic neuropathy. Neurology. 1981 Aug. 31(8):1057-8. [Medline].

  19. Moyer TP. Testing for arsenic. Mayo Clin Proc. 1993 Dec. 68(12):1210-1. [Medline].

  20. Lee AM, Fraumeni JF Jr. Arsenic and respiratory cancer in man: an occupational study. J Natl Cancer Inst. 1969 Jun. 42(6):1045-52. [Medline].

  21. Neubauer O. Arsenical cancer. Br J Cancer. 1947. 1:192-251:

  22. Barbara Fraser. Cancer cluster in Chile linked to arsenic contamination. The Lancet. February 18, 2012. 379:603.

Previous
Next
 
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.